Smisek Jeffery A's Form 4 filing
Finch Therapeutics Group, Inc. (FNCH) · filed Mar 29, 2024
- Accession no.
- 0000950170-24-038657
- Filed
- Mar 29, 2024
- Trade date
- Mar 28, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $21.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smisek Jeffery ACIK 0001193038 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted-average price of shares sold by the broker on behalf of the Reporting Person. The broker sold, in the aggregate on behalf of such Reporting Person, 6,642 shares in transactions ranging from $2.48 to $2.75 with a weighted-average price of $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the weighted-average price of shares sold by the broker on behalf of the Reporting Person's spouse. The broker sold, in the aggregate on behalf of such Reporting Person's spouse, 1,600 shares in transactions ranging from $2.56 to $2.76 with a weighted-average price of $2.61. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.